RxDoctor Payments Data

Zack Buckalew, MD

Internal Medicine · Alexandria, LANPI 1205829199

Payments from drug & device makers

$563in general payments, 2019–2025

Across 37 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$240
  • AbbVie$73
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$35
  • Dexcom, Inc.$35
  • Exact Sciences$29
  • Amgen$29
  • plus $122 from 7 others

What the payments were for

  • Food & beverage$563100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$563 in reported general payments places this provider in the 55th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$193,268
Medicare patients
342
Services billed
5,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$66,236
JardianceEmpagliflozin85$64,685
EliquisApixaban81$62,132
IngrezzaValbenazine Tosylate13$51,828
TrulicityDulaglutide27$33,532
XareltoRivaroxaban49$33,247
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$30,866
EntrestoSacubitril/Valsartan26$18,192
FarxigaDapagliflozin Propanediol11$17,671
NuedextaDextromethorphan Hbr/Quinidine18$14,135
MyrbetriqMirabegron12$13,369
LinzessLinaclotide21$12,310
Atrovent HfaIpratropium Bromide13$9,594
JanuviaSitagliptin Phosphate13$7,256
Breo ElliptaFluticasone/Vilanterol15$5,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$66,23669 claims
PfizerEliquis$240$62,13281 claims
AstraZenecaFarxiga$17$17,67111 claims
AbbVieLinzess$73$12,31021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →